Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
31,500
Employees31,500
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
31,500
Employees31,500

AMGN Key Statistics

Market cap
227.62B
Market cap227.62B
Price-Earnings ratio
26.35
Price-Earnings ratio26.35
Dividend yield
2.59%
Dividend yield2.59%
Average volume
2.83M
Average volume2.83M
High today
$416.22
High today$416.22
Low today
$386.52
Low today$386.52
Open price
$393.36
Open price$393.36
Volume
2.69M
Volume2.69M
52 Week high
$416.22
52 Week high$416.22
52 Week low
$269.77
52 Week low$269.77

Stock Snapshot

The current Amgen(AMGN) stock price is $409.70, with a market capitalization of 227.62B. The stock trades at a price-to-earnings (P/E) ratio of 26.35 and offers a dividend yield of 2.59%.

On 2026-08-05, Amgen(AMGN) stock traded between a low of $386.52 and a high of $416.22. Shares are currently priced at $409.70, which is +6.0% above the low and -1.6% below the high.

The Amgen(AMGN)'s current trading volume is 2.69M, compared to an average daily volume of 2.83M.

During the past year, Amgen(AMGN) stock moved between $269.77 at its lowest and $416.22 at its peak.

During the past year, Amgen(AMGN) stock moved between $269.77 at its lowest and $416.22 at its peak.

AMGN News

TipRanks 1h
Amgen price target raised to $450 from $385 at Scotiabank

Scotiabank analyst Louise Chen raised the firm’s price target on Amgen (AMGN) to $450 from $385 and keeps an Outperform rating on the shares. The firm remains p...

Simply Wall St 4h
Amgen Could Be 8% Overvalued Following Raised 2026 Guidance

Amgen (AMGN) stock is back in focus after the company beat Wall Street expectations in its second quarter 2026 report and raised full year revenue and earnings...

Amgen Could Be 8% Overvalued Following Raised 2026 Guidance
TipRanks 6h
Amgen price target raised to $400 from $390 at Wells Fargo

Wells Fargo analyst Mohit Bansal raised the firm’s price target on Amgen (AMGN) to $400 from $390 and keeps an Equal Weight rating on the shares. The firm notes...

Analyst ratings

49%

of 35 ratings
Buy
40%
Hold
48.6%
Sell
11.4%

More AMGN News

The Wall Street Journal 20h
Amgen Lifts Outlook on Strong Drug Sales, to End Early Development of Obesity Treatment

Amgen said it was halting the development of AMG 513, a potential obesity treatment currently in a phase 1 study. deena beasley / Reuters Amgen AMGN 2.94 %incr...

Amgen Lifts Outlook on Strong Drug Sales, to End Early Development of Obesity Treatment
Nasdaq 20h
Amgen Inc. Profit Rises In Q2

(RTTNews) - Amgen Inc. (AMGN) announced earnings for its second quarter that Increases, from last year The company's bottom line totaled $2.375 billion, or $4....

Amgen Inc. Profit Rises In Q2
Nasdaq 23h
Dow Analyst Moves: AMGN

The latest tally of analyst opinions from the major brokerage houses shows that among the 30 stocks making up the Dow Jones Industrial Average, Amgen is the #21...

Dow Analyst Moves: AMGN
Nasdaq 24h
See How Amgen Ranks Among Analysts' Top Dow 30 Picks

A study of analyst recommendations at the major brokerages shows that Amgen Inc (Symbol: AMGN) is the #17 broker pick, on average, out of the 30 stocks making u...

See How Amgen Ranks Among Analysts' Top Dow 30 Picks
TipRanks 24h
Amgen Extends Obesity Trial, Sharpening Its Long-Term Weight-Loss Bet

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident inv...

TipRanks 2d
Amgen’s AMG 127 Trial Signals a New Push Into Type 2 Diabetes

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident inv...

Simply Wall St 6d
How Investors May Respond To Amgen Repatha Expansion and 2026 Dividend Declaration

Amgen recently announced that its Board of Directors declared a US$2.52 per share dividend for the third quarter of 2026, payable on September 11, 2026 to share...

How Investors May Respond To Amgen Repatha Expansion and 2026 Dividend Declaration

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.